This roundtable series looks at therapies available in patients with later-line metastatic colorectal cancer, as discussed by key opinion leaders at virtual live events and interviews.

Options in Previously Treated Metastatic Colorectal Cancer

Using Trifluridine/Tipiracil Plus Bevacizumab in Third-Line CRC

November 04, 2025

During a live event, Michael J. Overman, MD, discussed the survival benefit of trifluridine/tipiracil /bevacizumab in metastatic colorectal cancer.

Recognizing How Treatment Differs in Community Setting for CRC

October 28, 2025

John L. Marshall, MD, discusses the challenges faced by oncologists in managing colorectal cancer treatments seen during a Case-Based Roundtable event.

Navigating Metastatic CRC Treatment Options in Later Lines

October 10, 2025

During a live event, Michael J. Overman, MD, discussed biomarker testing, ctDNA, and later-line treatment options for metastatic colorectal cancer.

Understanding Treatment Differences in Community Oncology for CRC

August 12, 2025

Marwan G. Fakih, MD, discusses barriers that create treatment differences in metastatic colorectal cancer for community oncologists.

Reviewing Available Data to Decide Sequence of CRC Therapies

July 28, 2025

John L. Marshall, MD, and Marwan G. Fakih, MD, discussed the landscape and sequencing of treatment for refractory colorectal cancer.

Key Takeaways of Trials in Metastatic CRC Explored

July 07, 2025

Marwan G. Fakih, MD, discusses the top takeaways from using combination treatment in metastatic colorectal cancer.

Physicians Consider Possible Outcomes of Treatment in Third-Line CRC

June 11, 2025

Marwan G. Fakih, MD, discusses topics in metastatic colorectal cancer from the Case-Based Roundtable meeting he moderated.

Unmet Needs and Therapy Modifications Relevant in the CRC Landscape

May 20, 2025

John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer.

Targeted Therapy Options Sometimes Underutilized in Metastatic CRC

April 09, 2025

John L. Marshall, MD, discusses the sequencing of targeted therapy for refractory metastatic colorectal cancer.

$SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC$

SUNLIGHT Findings Emphasize Role of VEGF Inhibition in Refractory CRC

March 26, 2025

John L. Marshall, MD, discusses the impact of the SUNLIGHT trial in patients with refractory metastatic colorectal cancer.